Oral dehydroepiandrosterone (DHEA) does not meaningfully raise serum testosterone levels in men, while it reliably increases circulating androgens in women. At Longevity Benchmark, we review clinical trial literature to separate measurable biomarker changes from commercial supplement marketing. Many consumers explore DHEA and testosterone to address age-related fatigue, declining muscle strength, or low libido. The biological response splits sharply between the sexes.
The Verdict
Trial Evidence on DHEA and Testosterone in Men
Randomized controlled trials consistently demonstrate that oral DHEA supplementation does not raise serum testosterone in men. In a landmark two-year study published in The New England Journal of Medicine, Nair et al. (2006) evaluated 87 elderly men with low baseline levels of sulfated dehydroepiandrosterone (DHEA-S) and bioavailable testosterone. Participants received oral DHEA, transdermal testosterone, or a matching placebo.
At 24 months, DHEA raised plasma DHEA-S by a median of 3.4 µg/mL (9.2 µmol/L) in men compared to placebo. However, DHEA had no significant effect on body composition measurements. The treatment failed to improve muscle strength, peak oxygen consumption, insulin sensitivity, or quality of life. The authors concluded that neither DHEA nor low-dose testosterone replacement has physiologically relevant beneficial effects in older adults. Shorter trials confirm this lack of androgenic conversion.
In a 12-month trial by Jankowski et al. (2008), 61 men aged 60 to 88 years received 50 mg daily of oral DHEA or placebo. DHEA increased DHEA-S, estrone, free estrogen index, and estradiol in men. Total testosterone and the free testosterone index did not increase. Resistance-training studies in younger cohorts show identical null outcomes.
Brown et al. (1999) administered 150 mg daily of DHEA or placebo to 19 young men during an eight-week whole-body resistance training protocol. Serum concentrations of free and total testosterone remained completely unaffected by DHEA supplementation. Both groups achieved identical gains in lean body mass and muscle strength. An earlier crossover study by Morales et al. (1994) tested 50 mg daily of DHEA for six months in men aged 40 to 70 years. The authors observed only a small rise in androstenedione, with no change in testosterone or dihydrotestosterone (DHT).
Metabolism explains this absence of systemic testosterone elevation. Using gas chromatography-mass spectrometry, Dehennin et al. (1998) found that oral conversion of DHEA to testosterone was real but minimal in men. Between 50% and 75% of the dose was recovered in urine within 24 hours as metabolites, reflecting heavy first-pass hepatic clearance. Similarly, the 12-month DHEAge study by Percheron et al. (2003) in 280 adults aged 60 to 80 years restored DHEA-S levels to young adult norms without improving muscle strength or muscle cross-sectional area.
In a meta-analysis of 25 randomized trials encompassing 1,353 elderly men, Corona et al. (2013) observed a modest reduction in fat mass that vanished after controlling for active hormonal metabolites. The authors found no benefits for bone health, sexual function, or quality of life. A subsequent meta-analysis by Li et al. (2020) reported a small weighted mean difference of 21.36 ng/dL in men. That shift is small against a typical adult male total testosterone concentration, and the meta-analysis reports no confidence interval for the male subgroup.
DHEA and Testosterone in Women Across Controlled Trials
Clinical trials show that oral DHEA supplementation reliably increases total and free testosterone levels in women. Because baseline circulating androgen levels are much lower in females, downstream prohormone conversion produces substantial percentage shifts. In the crossover study by Morales et al. (1994), women taking 50 mg daily experienced a two-fold increase in serum androstenedione, testosterone, and DHT. Men taking the same dose showed no such androgenic rise.
The most pronounced physiological increases occur in women with adrenal insufficiency. In a randomized crossover trial, Arlt et al. (1999) administered 50 mg daily of DHEA or placebo for four months to 24 women with primary or secondary adrenal failure. Treatment raised baseline concentrations of DHEA, DHEA-S, androstenedione, and testosterone into the normal range. The women experienced significant improvements in depression and anxiety scores, alongside increased sexual interest and satisfaction. Serum high-density lipoprotein (HDL) cholesterol and sex hormone-binding globulin (SHBG) dropped significantly during active therapy.
Meta-analyses confirm these endocrine effects in postmenopausal cohorts. A 2025 meta-analysis by He et al. (2025) pooling 21 studies in postmenopausal women found that DHEA increased serum testosterone by a weighted mean difference of 24.31 ng/dL (95% CI, 15.22 to 33.40). Estradiol also rose by 7.86 pg/mL (95% CI, 6.33 to 9.40). An earlier meta-analysis of elderly women by Hu et al. (2021) reported a similar testosterone increase of 17.52 ng/dL (95% CI, 6.61 to 28.43).
The systematic review by Scheffers et al. (2015) for the Cochrane Database of Systematic Reviews analyzed 28 trials in 1,273 peri- and postmenopausal women. DHEA therapy slightly improved sexual function compared to placebo, but failed to improve general quality of life. The Cochrane authors also identified an increased risk of androgenic side effects, primarily acne (odds ratio [OR] 3.77; 95% confidence interval (CI), 1.36 to 10.4). These androgenic outcomes remain specific to female biochemistry.
The DHEA and Testosterone Pathway and Enzymatic Conversion
The divergent hormonal responses between men and women stem directly from steroidogenic pathways and baseline endocrine production rates. As detailed by Tang et al. (2021), DHEA and its sulfated form DHEA-S are synthesized in the zona reticularis of the adrenal cortex, the gonads, and the brain. The precursor one step further upstream is handled separately in pregnenolone and TRT, where nobody has measured it before and after treatment. DHEA functions as a universal upstream prohormone for downstream sex steroids. Peripheral tissues express enzymes such as hydroxysteroid dehydrogenases, 5α-reductases, and aromatase that convert DHEA into androstenedione, testosterone, DHT, estrone, and estradiol.
DHEA itself does not bind or activate the androgen receptor. In a clinical practice guideline from the Endocrine Society, Wierman et al. (2014) stressed that DHEA, DHEA-S, and androstenedione are prohormones that do not activate the androgen receptor directly. The guideline summarized the clinical reality plainly. The administration of DHEA results in dose-dependent increases in circulating testosterone, DHT, and estrogens in women, whereas in men only circulating estrogens increase after DHEA therapy.
Where the dose ends up explains the split. In men, peripheral tissues route an oral DHEA dose mainly into androstenedione and the estrogens, or conjugate it for renal excretion, and the measurements bear that out: Jankowski's 12-month trial recorded rising estrone, estradiol and free estrogen index with no movement in total or free testosterone. Dehennin recovered 50% to 75% of an oral dose in urine within 24 hours as metabolites. Women start from a far lower circulating androgen baseline, so the same 50 mg is a large proportional addition, which is what the female meta-analyses measure against no change in the male trials.
Age-Related Decline in DHEA-S Concentrations
Circulating DHEA-S concentrations decline progressively across adult life in both sexes after peaking in early adulthood. In a cross-sectional investigation of 981 men and 481 women, Orentreich et al. (1984) established that serum DHEA-S peaks at ages 20 to 24 in men and ages 15 to 19 in women. Logarithmic mean concentrations reached 3,470 ng/mL in young men and 2,470 ng/mL in young women. Levels declined steadily across subsequent decades.
In individuals older than 70 years, mean levels fell to 670 ng/mL in men and 450 ng/mL in women. These figures represent approximately 81% lower concentrations in elderly men and 82% lower in elderly women compared to peak values. Longitudinal tracking confirms this downward trajectory. In a follow-up study of 97 men from the Baltimore Longitudinal Study of Aging, Orentreich et al. (1992) observed DHEA-S declines in 67% of participants over 13 years. Thirteen percent showed no change, and the remaining 19 participants increased. The authors noted wide, unexplained individual variability throughout the normal population.
In women, cohort data cited by Wierman et al. (2014) documented an average annual decline of 1.5% in the Melbourne Women's Midlife Health Project and 2.81% per year in the SWAN study. Marketing narratives frequently argue that restoring youthful DHEA-S concentrations will reverse physical aging. Clinical trials disprove that hypothesis. Restoring circulating DHEA-S to the reference range of young adults in Nair et al. (2006) and Percheron et al. (2003) failed to increase muscle mass, improve physical performance, or enhance vitality in older adults.
DHEA Concentrations During Exogenous Testosterone Therapy
No guideline position on DHEA alongside testosterone therapy could be verified either way. Some commercial protocols advocate combining DHEA with testosterone replacement therapy to preserve adrenal hormone output. The published clinical evidence does not support this practice.
To evaluate how exogenous androgens affect adrenal steroids, Muniyappa et al. (2006) analyzed nocturnal hormone secretory dynamics in 68 healthy older men and 36 older women over 26 weeks. In men receiving testosterone, nocturnal integrated DHEA secretion decreased significantly. However, morning serum DHEA-S concentrations remained unchanged. The investigators concluded that the clinical significance of sex steroid modulation on adrenal DHEA output remains unestablished.
The full text of the Endocrine Society's 2018 testosterone-therapy guideline (Bhasin et al.) is not publicly readable, so we cannot report what it says about DHEA in either direction. What is on the record is Muniyappa's finding above, and the absence of any trial evidence that DHEA is required, monitored or beneficial alongside testosterone replacement in men. Men evaluating low androgen symptoms can review our guide to signs of low testosterone and compare testosterone replacement therapy against testosterone boosters.
Clinical Indications with Documented Trial Evidence
While DHEA fails to elevate testosterone in men, DHEA has documented clinical utility in primary adrenal insufficiency, vulvovaginal atrophy, and specific reproductive protocols. In primary adrenal insufficiency, women lose both adrenal cortisol and adrenal androgen production. In clinical guidelines on primary adrenal insufficiency, Bornstein et al. (2016) suggest a six-month trial of DHEA replacement for women experiencing persistent low libido, depressive symptoms, or fatigue despite optimized glucocorticoid and mineralocorticoid therapy.
If the patient does not report sustained benefit after six months, clinicians discontinue DHEA. This recommendation carries low-quality evidence. In contrast, the 2014 Endocrine Society androgen guideline advised against routine DHEA use in adrenal insufficiency, illustrating ongoing professional debate.
The strongest regulatory endorsement belongs to a local prescription formulation. In November 2016, the Food and Drug Administration (FDA) approved INTRAROSA (prasterone) as a 6.5 mg vaginal insert for moderate to severe dyspareunia caused by menopause. Prasterone is the pharmaceutical nonproprietary name for synthetic DHEA. The insert works via local conversion in vaginal mucosal cells without producing significant systemic hormone elevation.
A 2026 meta-analysis of five randomized trials by Lemos et al. (2026) confirmed that intravaginal DHEA significantly reduced dyspareunia and vaginal dryness. The North American Menopause Society (NAMS) assigned vaginal DHEA a Level A recommendation for genitourinary syndrome of menopause in its 2020 position statement. Oral dietary supplements cannot be conflated with this approved local medication.
In reproductive medicine, DHEA has been investigated as an adjuvant during in vitro fertilization (IVF) for women classified as poor ovarian responders. A systematic review by Nagels et al. (2015) for Cochrane found an initial association with improved live birth rates (OR 1.88; 95% CI, 1.30 to 2.71 across eight trials). However, when investigators excluded trials with a high risk of performance bias, the effect lost statistical significance (OR 1.50; 95% CI, 0.88 to 2.56). A subsequent network meta-analysis by Zhang et al. (2020) in 19 trials using the Bologna criteria reported increased clinical pregnancy rates (OR 2.46; 95% CI, 1.16 to 5.23) with DHEA adjuvant therapy. Definitive clinical consensus remains unresolved.
| Clinical Indication | Population | Dose the Trials Administered | Hormonal and Clinical Outcomes | Primary Evidence |
|---|---|---|---|---|
| Primary Adrenal Insufficiency | Women with adrenal failure | Arlt 1999 gave oral DHEA 50 mg/day for four months | Restored DHEA, DHEA-S, and testosterone to normal reference ranges; improved mood scores and sexual interest | Arlt et al. (1999); Bornstein et al. (2016) |
| Vulvovaginal Atrophy / Dyspareunia | Postmenopausal women | FDA-approved label: intravaginal prasterone 6.5 mg/day | Local conversion in vaginal mucosa; significant reduction in dyspareunia (MD -0.40) and vaginal dryness without systemic accumulation | FDA NDA 208470; Lemos et al. (2026); NAMS (2020) |
| Poor Ovarian Response in Assisted Reproduction | Women undergoing IVF | Trials gave oral DHEA as an IVF adjuvant | Initial association with increased clinical pregnancy rates; effect weakened and non-significant when high-bias trials were removed | Nagels et al. (2015); Zhang et al. (2020) |
| Age-Related Androgen Decline in Men | Older men with low DHEA-S | Trials gave oral DHEA 50 to 150 mg/day | DHEA-S increased; total and free testosterone remained unchanged; no improvement in strength, lean mass, or quality of life | Nair et al. (2006); Jankowski et al. (2008); Corona et al. (2013) |
Safety Signals and Physiological Blood Markers
Clinical trials indicate that oral DHEA carries specific metabolic, androgenic, and lipid effects that warrant clinical oversight. The most dependable lipid change is a reduction in circulating HDL cholesterol in women. In a systematic review and dose-response meta-analysis of 23 randomized trials, Qin et al. (2020) demonstrated that oral DHEA significantly reduced HDL cholesterol (WMD -3.1 mg/dL; 95% CI, -4.9 to -1.3).
When stratified by sex, the reduction occurred exclusively in women (WMD -5.1 mg/dL; 95% CI, -7.2 to -3.0), whereas men experienced no significant change (WMD 0.13 mg/dL). Total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides were unaffected. Single trials by Arlt et al. (1999) and Morales et al. (1994) corroborated this female-specific HDL decline. Dermatological side effects also occur predominantly in female users. The 2015 Cochrane review by Scheffers et al. documented a significant increase in androgenic symptoms, mainly acne (OR 3.77; 95% CI, 1.36 to 10.4).
Regarding hepatic safety, a meta-analysis of randomized trials by Chen et al. (2021) found that DHEA did not alter liver transaminases, with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) remaining stable across trial arms. Brown et al. (1999) similarly noted no change in liver transaminases in young men taking 150 mg daily for eight weeks. The primary safety caution centers on hormone-sensitive tissues.
Because DHEA metabolizes downstream into estradiol and testosterone, regulators warn against its use in patients with a history of hormone-dependent cancers. The FDA label for Intrarosa contraindicates estrogen therapy in women with known or suspected breast cancer, noting that testosterone and estradiol metabolites cause cancer in animal studies. NAMS emphasizes that long-term endometrial safety data for DHEA beyond one year remain unavailable. Importantly, no randomized clinical trial has established incident cancer rates for oral DHEA supplements in humans.
Monitoring practices reflect these hormonal conversions. The only formal guideline recommendation on monitoring appears in Bornstein et al. (2016) for women with adrenal insufficiency, advising morning serum DHEA-S testing before the daily dose to target midnormal ranges. Wierman et al. (2014) cautioned that correspondence between standard clinical immunoassays and liquid chromatography-mass spectrometry is poor for DHEA-S, requiring cautious interpretation of absolute values. No medical guideline establishes a target DHEA-S concentration for healthy adults taking over-the-counter supplements.
Product Quality Testing and Regulatory Classifications
Over-the-counter DHEA products exhibit widespread variability in active ingredient potency and carry strict regulatory restrictions globally. In an analytical evaluation conducted by FDA scientists, Thompson and Carlson (2000) tested 45 commercial DHEA dietary supplements using liquid chromatography. Assay values ranged from 0% to 109.5% of declared label amounts, with a mean content of 91.1%.
Earlier testing reported by Olech and Merrill (2005), citing an analysis by Parasrampuria et al. (1998), identified products containing zero active DHEA while one preparation contained 150% of its claimed amount. DHEA also surfaces as an undeclared adulterant in other products. Using high-resolution mass spectrometry, Odoardi et al. (2015) analyzed 30 unlabelled dietary supplements and identified undeclared DHEA in 12 formulations.
The FDA continues to penalize misleading commercial marketing. In August 2024, the agency issued a warning letter to manufacturer AnuMed International LLC for distributing unapproved new drugs and marketing misbranded topical DHEA creams with unsupported hormone balancing and anti-aging claims. Legal classifications differ sharply across international borders.
In the United States, the Anabolic Steroid Control Act of 2004 (Pub. L. 108-358) and Drug Enforcement Administration (DEA) regulations under 21 CFR § 1300.01 explicitly exempt DHEA from the statutory definition of an anabolic steroid, permitting retail supplement sales. Other nations enforce strict prohibitions.
In the United Kingdom, DHEA (prasterone) is scheduled as a Class C controlled drug under the Misuse of Drugs Act 1971. Canada classifies prasterone as a Schedule IV controlled substance under the Controlled Drugs and Substances Act. Australia regulates prasterone as a Schedule 4 Prescription Only Medicine within its Poisons Standard.
Athletes face absolute sporting bans. The World Anti-Doping Agency (WADA) prohibits prasterone at all times under section S1.1 of the 2026 Prohibited List as an anabolic androgenic steroid. Testing by Dehennin et al. (1998) noted that a single replacement dose can clear screening thresholds within eight hours due to rapid metabolism, complicating anti-doping detection.
Clinical Candidacy and Evidentiary Boundaries
Evaluating clinical candidacy requires identifying who should avoid DHEA supplementation based on documented trial outcomes. First, for men seeking elevated testosterone, muscle hypertrophy or athletic enhancement, the trials that measured those endpoints found nothing: serum testosterone was unchanged in Brown 1999, Morales 1994 and Jankowski 2008, and Nair 2006 recorded no gain in strength or lean mass over placebo across two years.
Second, for anyone with a personal history of hormone-dependent malignancy the evidence is regulatory rather than measured: the INTRAROSA label warns that estrogen is a metabolite of prasterone and that the product has not been studied in women with a history of breast cancer, and no randomised trial or cohort study has measured a cancer risk for oral DHEA in either direction. Third, competitive athletes subject to WADA anti-doping regulations cannot take DHEA under any circumstance. Finally, healthy adults seeking broad anti-aging or cognitive benefits gain no documented functional improvements from supplementation.
If future multi-year randomized controlled trials demonstrate that oral DHEA reliably increases serum total or free testosterone in men while delivering measurable functional gains in muscle mass, bone density, or physical performance, our editorial verdict would change. Similarly, if long-term prospective trials establish cardiovascular safety and demonstrate that female HDL suppression produces no adverse vascular outcomes, our guidance for women would expand. The measurements clinicians are described as following in these trials are serum total and free testosterone and morning DHEA-S; our guides to the men's hormone panel and to SHBG set out what each one reports and what it does not.
Frequently Asked Questions
Does DHEA increase testosterone?
It depends on sex, and that is the whole answer. In men, randomised controlled trials that measured serum testosterone found it unchanged, which the next question sets out in detail. In women, the same oral supplement raises total testosterone, free testosterone and dihydrotestosterone (DHT) measurably, which the question after that covers. The divergence is quantitative: a man's testicular output dwarfs anything the adrenal cortex contributes, while in women adrenal prohormones supply a substantial share of androgen precursors, so the same dose lands very differently. Almost every claim made about DHEA and testosterone is true of one sex and false of the other, which is why the two are answered separately here.
Does DHEA increase testosterone in men?
No, clinical trials show that oral DHEA does not raise serum testosterone in men. In a two-year randomized controlled trial published by Nair et al. in The New England Journal of Medicine, elderly men receiving oral DHEA experienced significant elevations in sulfated DHEA (DHEA-S) but showed no improvements in body composition, physical performance, or muscle strength. Subsequent 12-month trials by Jankowski et al. and Percheron et al. confirmed that while DHEA-S and circulating estrogens rise in men taking 50 mg daily, total and free testosterone remain unchanged. In younger men undergoing resistance training, Brown et al. found that 150 mg daily of DHEA did not alter total or free testosterone or enhance muscular adaptations compared to placebo.
Does DHEA raise testosterone in women?
Yes, oral DHEA reliably elevates circulating testosterone and other androgens in women. Because baseline androgen concentrations are naturally lower in women, adrenal prohormones contribute a substantial portion of overall circulating levels. In a crossover study by Morales et al., women receiving 50 mg daily of DHEA experienced a two-fold increase in serum testosterone, androstenedione, and dihydrotestosterone. Meta-analyses in postmenopausal women by He et al. and Hu et al. documented average serum testosterone increases between 17 and 24 ng/dL. In women with adrenal insufficiency, a landmark trial by Arlt et al. showed that 50 mg daily restored low testosterone concentrations into the normal physiological reference range, accompanied by improvements in mood and sexual interest.
Does DHEA turn into oestrogen instead of testosterone?
In men, oral DHEA preferentially converts into estrogens and intermediate metabolites rather than accumulating as active testosterone. Peripheral tissues contain steroidogenic enzymes including aromatase, which converts downstream androstenedione into estrone and estradiol. In a 12-month trial by Jankowski et al., older men receiving 50 mg daily of oral DHEA exhibited significant increases in serum estrone, estradiol, and the free estrogen index, while total and free testosterone concentrations did not rise. Furthermore, pharmacokinetic studies by Dehennin et al. show that the majority of an oral DHEA dose undergoes rapid first-pass hepatic metabolism into sulfated and glucuronidated conjugates excreted in urine, preventing significant conversion into circulating systemic testosterone in male physiology.
Does DHEA-S decline with age, and does replacing it help?
Circulating DHEA-S concentrations decline substantially with age, but clinical trials show that restoring youthful blood levels does not reverse physical aging. Cross-sectional data from Orentreich et al. showed that DHEA-S peaks between ages 20 and 24 in men and ages 15 and 19 in women, falling by roughly 81% and 82% respectively by age 70. Longitudinal data from the Baltimore Longitudinal Study of Aging confirmed this decline in two-thirds of healthy men. However, when randomized controlled trials by Nair et al. and Percheron et al. administered 50 mg daily to restore DHEA-S to youthful reference ranges, participants experienced no improvements in muscle mass, physical performance, insulin sensitivity, or quality of life.
Is DHEA banned in sport?
Yes, DHEA is strictly prohibited in competitive sports. The World Anti-Doping Agency (WADA) classifies prasterone (DHEA) under section S1.1 of its 2026 Prohibited List as an Anabolic Androgenic Steroid. It is banned at all times, both in-competition and out-of-competition, for all athletes governed by the World Anti-Doping Code. Sanctions apply regardless of whether an athlete consumes DHEA as a standalone supplement or as an undeclared ingredient in a multi-ingredient product. Research by Dehennin et al. noted that oral DHEA metabolizes rapidly, with single replacement doses clearing urinary screening thresholds within eight hours, though anti-doping laboratories test for multiple metabolites and altered steroid profiling ratios to detect use.
Is DHEA a prescription drug or a supplement?
The regulatory status of DHEA depends on the jurisdiction and the specific product formulation. In the United States, oral DHEA is legally sold over the counter as a dietary supplement because the Anabolic Steroid Control Act of 2004 specifically excluded dehydroepiandrosterone from the statutory definition of an anabolic steroid. However, the FDA approved INTRAROSA (prasterone) in 2016 as a prescription-only 6.5 mg vaginal insert for dyspareunia. Internationally, regulations are far stricter: DHEA is classified as a Class C controlled drug in the United Kingdom, a Schedule IV controlled substance in Canada, and a Schedule 4 Prescription Only Medicine in Australia, making over-the-counter retail sale unlawful in those countries.
Does DHEA help with fertility or IVF outcomes?
The evidence for DHEA in reproductive medicine is mixed and limited primarily to women classified as poor ovarian responders undergoing in vitro fertilization (IVF). A 2015 Cochrane systematic review by Nagels et al. initially found that DHEA pre-treatment was associated with improved live birth or ongoing pregnancy rates (odds ratio 1.88). However, when the authors performed a sensitivity analysis excluding trials with a high risk of performance bias, the effect lost statistical significance (odds ratio 1.50). A 2020 network meta-analysis by Zhang et al. in 19 trials using the Bologna criteria observed higher clinical pregnancy rates with DHEA adjuvant therapy, but guideline bodies caution that larger, standardized trials are needed.